Showing 1491-1500 of 9797 results for "".
Nemluvio Gains Two Major Indications in Europe
https://practicaldermatology.com/series/dermwire-tv/nemluvio-gains-two-major-indications-in-europe/32982/In this week's DermwireTV, Nemluvio is approved for two new indications in Europe; new patient-centric guidelines for generalized pustular psoriasis (GPP) management are unveiled; and in our C-Suite Chats feature, we are joined by the Co-Founder and CEO of Veradermics.Leadership Without Authority:Influencers of Culture in Your Practice
https://practicaldermatology.com/issues/may-june-2025/leadership-without-authority-influencers-of-culture-in-your-practice/35924/Influencers in popular culture demonstrate how individuals without formal authority can shape trends, ideas, and behavior.AAD Leaders Discuss New Goals and Initiatives
https://practicaldermatology.com/series/dermwire-tv/aad-leaders-discuss-new-goals-and-initiatives/33154/In this week's DermwireTV, leaders of the American Academy of Dermatology (AAD) discuss the key issues facing the specialty; a new study examines nicotinamide exposure and the risk of major adverse cardiovascular events; and in our C-Suite Chats segment, we hear from an Executive Director at TakeLip Lifts: A Procedure to Consider
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/lip-lifts-a-procedure-to-consider/23033/Consider referring for a surgical lip lift when fillers don’t suffice.Patient Experience with PDT
https://practicaldermatology.com/series/pdt-in-practice/patient-experience-pdt/28863/Dr. Joel L. Cohen discusses how he implemented photodynamic therapy and describes the patient experience with it, including scheduling considerations.Drug-Induced Dermatomyositis
https://practicaldermatology.com/topics/atopic-dermatitis/drug-induced-dermatomyositis/23357/It’s common practice to screen for underlying malignancy in dermatomyositis, but it is also important to look for drug-induced disease.The View from Under the Hood
https://practicaldermatology.com/issues/january-february-2025/the-view-from-under-the-hood/32967/As 2025 brings new approvals for treatments for hidradenitis suppurativa, chronic spontaneous urticaria, psoriatic arthritis, and several other diseases that need answers, this is a good time for us to remember that the most important approach to treatment starts with the right diagnosis.DermWire TV Extra: 3-Year Clinical Data on Lebrikizumab
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-extra-3-year-clinical-data-lebrikizumab/28648/Study author Melinda Gooderham, MSc, MD, FRCPC, discusses the new three-year clinical data presented at the European Academy of Dermatology & Venereology (EADV) Congress on the efficacy and safety of lebrikizumab, which the FDA recently approved on September 13 for adults and adolescents with moRosacea Unveiled: A YoungMD Connect Open Discussion with Dr. Corey Hartman
https://practicaldermatology.com/youngmd-connect/wrap-ups/rosacea-unveiled-a-youngmd-connect-open-discussion-with-dr-corey-hartman/27168/In his YoungMD Connect virtual session on the topic of rosacea, Dr. Corey Hartman shared extensive experience with the eager viewing audience. Topics discussed included treating patients with rosacea, including those with skin of color, as well as clinical pearls on diagnosing and managing this commNIH Analysis Examines Association Between AD and Comorbidities
https://practicaldermatology.com/programs/practical-dermatology-atopic-dermatitis/nih-analysis-examines-association-between-ad-and-comorbidities/27113/In this week's DermwireTV, new NIH data looks at the association between AD and several health conditions; a study evaluates the effect of lebrikizumab monotherapy in patients with moderate-to-severe AD over 16 weeks; and Andrew Mastro provides tips on how to optimize the first 5 minutes with a pati